Patient decision aid: Type 2 diabetes blood pressure control

Similar documents
Atrial fibrillation patient decision aid: Antithrombotic therapy

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Primary hypertension in adults

NICE BHS Hypertension guidelines 2011 update

5.2 Key priorities for implementation

ADVANCE post trial ObservatioNal Study

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

American Diabetes Association 2018 Guidelines Important Notable Points

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Using the New Hypertension Guidelines

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

MPharmProgramme. Hypertension (HTN)

Hypertension Clinical case scenarios for primary care

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.

The problem of uncontrolled hypertension

GETTING THE MOST FROM BLOOD PRESSURE MEDICINES

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Hypertension AN OVERVIEW

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator

Hypertension. Penny Mosley MRPharmS

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Summary of recommendations

Combination Therapy for Hypertension

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator

Cedars Sinai Diabetes. Michael A. Weber

Blood Pressure Acre Surgery Diviash Thakrar

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

Dr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?

Diabetes and Hypertension

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Incidental Findings; Management of patients presenting with high BP. Phil Swales

The Metabolic Syndrome: Is It A Valid Concept? YES

CVD Risk of Hypertension. Regina Giblin CVD Clinical Development Coordinator

Update on Current Trends in Hypertension Management

Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study

Your Numbers Tell Your Story. Jennifer Stafford, RN Legacy Meridian Park Medical Center

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Treating Hypertension in Individuals with Diabetes

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

High blood pressure and stroke

NICE guideline Published: 2 December 2015 nice.org.uk/guidance/ng28

Helping you to lower your blood pressure. COVER.indd 1 16/07/ :29

Diabetes. Ref HSCW 024

ADVANCES IN MANAGEMENT OF HYPERTENSION

Estimated number of people with hypertension. Significantly higher than the. Proportion. diagnosed with. hypertension

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Hypertension Management in Minorities: Closing the gap

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

hypertension Head of prevention and control of CVD disease office Ministry of heath

Andhra Pradesh, India Corresponding Author: Dr. S. Parveen *

major public health burden

What is DIABETES? Gwen Hall Diabetes Specialist Nurse Haslemere Health Centre Surrey

Hypertension Guidelines: International; African,?Kenyan

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

ADVANCES IN MANAGEMENT OF HYPERTENSION

Jared Moore, MD, FACP

Hypertension Profile. NHS High Weald Lewes Havens CCG. Background

North of Tyne and Gateshead Guidelines for Management and Diagnosis of Hypertension Reviewed August 2017

Guideline scope Hypertension in adults (update)

SECONDARY HYPERTENSION

How many spoonfuls of sugar? A Bert s-eye view of prescribing to manage blood sugar

Diabetes Mellitus: A Cardiovascular Disease

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

Guideline for the diagnosis and management of hypertension in adults

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Prevention of Heart Failure: What s New with Hypertension

CLINICAL GUIDELINE. Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension.

INTRODUCING HIGH BLOOD PRESSURE

Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care

First line treatment of primary hypertension

The Clinical Unmet need in the patient with Diabetes and ACS

Causes of Poor BP control Rates

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Hypertension Update Background

Diabetes and stroke. What is diabetes? What are the symptoms of diabetes? Stroke Helpline: Website: stroke.org.uk

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Dr Doris M. W Kinuthia

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Outcomes of diabetes care in England and Wales. A summary of findings from the National Diabetes Audit : Complications and Mortality reports

BLOOD PRESSURE. Unit 3: Transportation and Respiration

Antihypertensive Trial Design ALLHAT

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertension Update. Aaron J. Friedberg, MD

Modern Management of Hypertension

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126.

STANDARD treatment algorithm mmHg

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

What if we could prescribe information that supported patients to understand and own their diabetes?

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

(Would you like to include: <5mm, 5-10mm?)

Steps Against Recurrent Stroke (STARS)

NICE to. know... The facts you need to make the most of your diabetes care.

ASSeSSing the risk of fatal cardiovascular disease

Transcription:

Patient decision aid: Type 2 diabetes blood pressure control What this patient decision aid is for? This decision aid is intended to assist healthcare professionals in consultations with patients who have type 2 diabetes. It relates to patients considering whether or not to tightly control their blood pressure (BP). How much does controlling BP improve outcomes in patients with type 2 diabetes? In the BP-lowering arm of UKPDS tight control of BP achieved a reduction in risk of stroke, diabetes related deaths and microvascular events. 1 The BP-lowering arm of UKPDS included 1148 hypertensive patients with type 2 diabetes. It compared tight control of BP (aiming for less than 150/85mmHg) with less tight control (aiming for less than 180/105mm Hg), for a median follow up of 8.4 years. 1 A benefit was seen for tight BP control compared with less tight control. Relative risk reductions were 24% for diabetes related end points (95% confidence interval [CI] 8 38%; p=0.0046), 32% in deaths related to diabetes (95% CI 6 51%; p=0.019), 44% in strokes (95% CI 11 65%; p=0.013), and 37% in microvascular end points (95% CI 11 56%; p=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. 1 The diagrams (Cates plots) on the next pages give a pictorial representation of the absolute risk reductions for these results. They show what happens with and without tight BP control in a group of 100 people with type 2 diabetes over approximately 8 years. So tight control of BP produced a statistically significant benefit in terms of cardiovascular outcomes and diabetic mortality, unlike blood glucose control with sulphonylurea or insulin in another arm of the study which did not achieve any significant benefits in terms of mortality or cardiovascular outcomes. 2 What BP Targets? NICE guidelines for type 2 diabetes set a target to aim for in people with type 2 diabetes of less than 130/80mmHg if they have kidney, eye or cerebrovascular disease, or less than140/80mmhg if they don t have such damage. 3 However, both these targets can be challenging to meet, and agreeing individualised targets is important, as any reduction in BP towards these levels is likely to be beneficial. NPC materials may be downloaded/copied freely by people employed by the NHS in England for purposes that support NHS activities in England. Any person not employed by the NHS, or who is working for the NHS outside England, who wishes to download/copy NPC materials for purposes other than their personal use should seek permission first from the NPC. Email: copyright@npc.nhs.uk Copyright 2009. T2D PDA bp 2009_final.doc 29/05/2009 Page 1 of 5

What treatments? Lifestyle advice should be offered in the first instance. This includes advice on diet, exercise, stopping smoking and reducing alcohol, caffeine and salt intake. If drug treatment is needed, the first-line antihypertensive agent for most people with type 2 diabetes is a once-daily, generic ACE inhibitor. Exceptions are people of African-Caribbean descent or women for whom there is a possibility of becoming pregnant. 3 If individually agreed BP targets are not met, it is recommended that treatment is stepped up to dual therapy with an ACE inhibitor and either a thiazide diuretic or a calcium-channel blocker, then triple therapy with all three of these. 3 Most people with type 2 diabetes will need more than one antihypertensive to reduce their BP sufficiently, and a generic ACE inhibitor plus bendroflumethiazide 2.5 mg once daily seems a reasonable choice for many. If people are already on antihypertensives at the time of diagnosis, changes should only be made to their medication if there is poor BP control or if current medications are not appropriate because of metabolic problems or microvascular complications (for example, they have kidney damage and should, therefore, be on an ACE inhibitor). 3 Source of images The images have been produced using Dr Chris Cates software VisualRx 3.0. More information can be obtained from the website www.nntonline.net. References 1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703 713. 2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837 853. 3. NICE. Type 2 diabetes: the management of type 2 diabetes (update). Clinical Guideline 66. May 2008. NPC materials may be downloaded/copied freely by people employed by the NHS in England for purposes that support NHS activities in England. Any person not employed by the NHS, or who is working for the NHS outside England, who wishes to download/copy NPC materials for purposes other than their personal use should seek permission first from the NPC. Email: copyright@npc.nhs.uk Copyright 2009. T2D PDA bp 2009_final.doc 29/05/2009 Page 2 of 5

Tight control of BP death from diabetic complications Imagine 100 people like those in this part of UKPDS. Without tight control of their BP about 16 (16%) of them would die from a diabetes related complication over the next 8 years. So, 84 (84%) of them would not die from a diabetic complication (100 16 = 84). About 5 people will be saved from dying from diabetes complications (the yellow faces). About 84 people will not die from diabetes complications but would not have done even if they had not tightly controlled their BP (the green faces). About 11 people will still die from diabetes complications, even though they tightly controlled their BP (the red faces). not die from a diabetic saved from dying of a diabetic complication because they tightly die of a diabetic T2D PDA bp 2009_final.doc 29/05/2009 Page 3 of 5

Tight control of BP stroke Imagine 100 people like those in this part of UKPDS. Without tight control of their BP about 9 (9%) of them would have a stroke over the next 8 years. So, 91 (91%) of them would not have a stroke (100 9 = 91). About 4 people will be saved from having a stroke (the yellow faces). About 91 people will not have a stroke but would not have done even if they had not tightly controlled their BP (the green faces). About 5 people will still have a stroke even though they tightly control their BP (the red faces). not have a stroke whether or not they tightly saved from having a stroke because they tightly have a stroke whether or not they tightly T2D PDA bp 2009_final.doc 29/05/2009 Page 4 of 5

Control of BP microvascular complications Imagine 100 people like those in this part of UKPDS. Without tight control of their BP about 14 (14%) of them will have a microvascular complication, eg need retinal photocoagulation, over the next 8 years. So, 86 (86%) of them would not have a microvascular complication (100 14 = 86). About 5 people will be saved from having a microvascular complication (the yellow faces). About 86 people will not have a microvascular complication but would not have done even if they had not tightly controlled their BP (the green faces). About 9 people will still have a microvascular complication, even though they tightly control their BP (the red faces). not have a microvascular saved from having a microvascular complication because they tightly have a microvascular T2D PDA bp 2009_final.doc 29/05/2009 Page 5 of 5